Ascendis Pharma A/S (ASND)

NasdaqGS • Currently down 0.56 (-0.21%) in today's trading session

1 member of Congress has disclosed 7 trades in Ascendis Pharma A/S (ASND) via STOCK Act filings. The most recent disclosure was a sale by Gary J. Palmer on 10 October 2018. Aggregate disclosed activity totals roughly $32K in purchases and $24K in sales (midpoint estimates from bracketed disclosure amounts).

Ascendis Pharma A/S is currently trading at $270.56, positioned at 88% of its 52-week range ($186.05 – $282.15).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$270.56
24h Change
-0.56 (-0.21%)
52 Week Range
$186.05–$282.15
View on NASDAQ

Ascendis Pharma A/S Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ASND

Select to highlight on chart
5 transactions
Compliance: 43%
Gary J. Palmer10 Oct 201816 Oct 2019SaleStock$1,001 - $15,000N/A
Gary J. Palmer10 Oct 201810 Sept 2019SaleStock$1,001 - $15,000N/A
Gary J. Palmer5 Oct 20187 Nov 2018SaleStock$1,001 - $15,000N/A
Gary J. Palmer6 Aug 201829 Sept 2018PurchaseStock$1,001 - $15,000N/A
Gary J. Palmer12 Jul 201829 Sept 2018PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$16.8B

Volume

723.51K

Beta

0.38

P/E Ratio

-111.80

Fundamentals

EPS

$-2.42

Div. Yield

-

Open

$267.96

Day Range

$265.22 – $271.17

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
DK
CEO
Jan Moller Mikkelsen
IPO Date
2015-01-28
Website
ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals...

Earnings

Next Report

Q3 2026

11 Nov

EPS Est.

$1.13

Rev. Est.

$485.7M

Days Until

65

Recent Quarters

Q2 202613 Aug
EPS$3.29
Beat 92.4%
Q1 20267 May
EPS$0.32
Beat 70.6%
Q4 202511 Feb
EPS$-0.64
Miss 966.7%
Q3 202512 Nov
EPS$-1.17
Miss 185.4%
Q2 20257 Aug
EPS$-0.93
Beat 34.5%
Q1 20251 May
EPS$-1.66
Miss 6.4%
Q4 202412 Feb
EPS$-0.68
Beat 43.3%
Q3 202414 Nov
EPS$-1.81
Beat 1.1%
Q2 20243 Sept
EPS$-2.05
Miss 33.1%
Q1 20242 May
EPS$-2.48
Miss 53.3%
Q4 20237 Feb
EPS$-1.66
Beat 24.1%
Q3 20237 Nov
EPS$-3.08
Miss 21.0%
Q2 20235 Sept
EPS$-2.35
Beat 12.3%
Q1 202327 Apr
EPS$-2.18
Beat 25.6%
Q4 202216 Feb
EPS$-3.96
Miss 44.5%
Q3 20222 Nov
EPS$-3.05
Miss 21.0%
Q2 202210 Aug
EPS$-1.50
Beat 31.5%
Q1 202211 May
EPS$-2.31
Miss 10.5%
Q4 20212 Mar
EPS$-2.06
Beat 20.1%
Q3 202110 Nov
EPS$-1.69
Beat 35.8%
Q2 202125 Aug
EPS$-3.01
Miss 9.4%
Q1 202127 May
EPS$-1.43
Beat 31.6%
Q4 202010 Mar
EPS$-3.15
Miss 71.2%
Q3 202011 Nov
EPS$-2.73
Miss 46.2%
Q2 202027 Aug
EPS$-2.34
Miss 36.8%
Q1 202019 May
EPS$-1.44
Beat 2.2%
Q1 20201 Apr
EPS$-1.85
Miss 16.4%
Q3 201918 Nov
EPS$-0.59
Beat 55.5%
Q2 201928 Aug
EPS$-1.38
Miss 3.3%
Q1 201930 May
EPS$-1.38
Miss 24.0%
Q1 20193 Apr
EPS$-0.85
Beat 24.0%
Q3 201828 Nov
EPS$-0.92
Beat 24.3%
Q2 201829 Aug
EPS$-0.64
Beat 38.9%
Q1 201830 May
EPS$-1.25
Miss 39.0%
Q4 201728 Mar
EPS$-1.13
Miss 15.0%
Q3 201716 Nov
EPS$-1.22
Miss 40.5%
Q2 201718 Aug
EPS$-1.10
Miss 30.6%
Q1 201723 May
EPS$-0.93
Miss 10.7%
Q4 201622 Mar
EPS$-0.55
Beat 9.8%
Q3 201630 Nov
EPS$-0.85
Miss 17.6%
Q2 201631 Aug
EPS$-0.67
Beat 13.0%
Q1 201619 May
EPS$-1.01
Miss 55.2%
Q3 201531 Dec
EPS$-0.52
Q3 201512 Nov
EPS$-0.35
Beat 45.0%
Q2 201524 Aug
EPS$-0.79
Miss 42.9%
Q1 201518 May
EPS$0.08
Beat 118.0%
Q4 201425 Mar
EPS$-0.71
Q2 201430 Sept
EPS$-0.15
Q1 201430 Jun
EPS$-0.27
Q4 201331 Mar
EPS$-0.06
Q3 201331 Dec
EPS$0.28
Q2 201330 Sept
EPS$0.09
Q1 201330 Jun
EPS$0.07
Q4 201231 Mar
EPS$0.07

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ASND

Which members of Congress have traded ASND?
1 member of Congress has disclosed 7 trade in Ascendis Pharma A/S (ASND) under the STOCK Act: Gary J. Palmer.
When was ASND most recently disclosed by Congress?
The most recent ASND disclosure was a sale by Gary J. Palmer on 10 October 2018.
What is the total disclosed congressional trading volume for ASND?
Members of Congress have disclosed approximately $32K in ASND purchases and $24K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ASND?
This ASND page updates as soon as new STOCK Act disclosures are filed for Ascendis Pharma A/S. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.